LY2623091
DrugAdministered orally
Other names: Mineralocorticoid Receptor Antagonist
NCT Number: NCT02194465
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2623091 in participants with high blood pressure.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brampton, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Administered orally
Other names: Mineralocorticoid Receptor Antagonist
Administered orally
Other names: LY450190
Administered orally
Administered orally
Time frame: Baseline, 4 Weeks
Change from baseline in SBP as measured by a cuff. Least squares (LS) mean change from baseline was calculated using a mixed model repeating measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 4 Weeks
Change from baseline in DBP as measured by a cuff. LS mean change from baseline was calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 4 Weeks
The LS mean change in blood pressure is calculated after adjusting for baseline, treatment and race using an analysis of covariance (ANCOVA).
Time frame: Baseline, 4 Weeks
Potassium measurement as measured by standard laboratory tests. The LS mean change in potassium is calculated using MMRM with adjustment for baseline, treatment, visit, treatment*visit and race.
Time frame: 2 hours post-dose at 4 Weeks
Eli Lilly and Company
Industry
A Randomized, Placebo-Controlled, Double-Blinded, Parallel, Phase 2a Study to Evaluate the Safety and Efficacy of LY2623091 in Patients With Primary Hypertension
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07272486
Cardiovascular Diseases, Disease Attributes
Ankara, Çankaya, Turkey (Türkiye)
View Trial DetailsNCT06884085
Cardiovascular Diseases, Essential Hypertension
Seoul, South Korea
View Trial DetailsNCT03310684
Body Weight, Cardiomegaly
Winston-Salem, North Carolina, United States
View Trial DetailsNCT05683301
Cardiovascular Diseases, Essential Hypertension
Guntur, Andhra Pradesh, India
View Trial Details